Cargando…

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

More women are living with and surviving breast cancer, because of improvements in breast cancer care. Trastuzumab (Herceptin®▾) has significantly improved outcomes for women with HER2-positive tumours. Concerns about the cardiac effects of trastuzumab (which fundamentally differ from the permanent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, A L, Barlow, M, Barrett-Lee, P J, Canney, P A, Gilmour, I M, Robb, S D, Plummer, C J, Wardley, A M, Verrill, M W
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653760/ https://www.ncbi.nlm.nih.gov/pubmed/19259090 http://dx.doi.org/10.1038/sj.bjc.6604909

Ejemplares similares

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
por: Clayton, A J, et al.
Publicado: (2004)

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
por: Smith, Lesley A, et al.
Publicado: (2010)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Trastuzumab-associated cardiac events in the Persephone trial
por: Earl, Helena M, et al.
Publicado: (2016)

Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
por: Vu, Thuy, et al.
Publicado: (2012)

Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series
por: Stravodimou, Athina, et al.
Publicado: (2014)

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
por: Diessner, J, et al.
Publicado: (2014)

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results
por: Hiller, Louise, et al.
Publicado: (2018)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Trastuzumab administration during pregnancy: an update
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network
por: Borley, A, et al.
Publicado: (2014)

An updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013–2018
por: Kwiatkowska, M., et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Updated UK Recommendations for HER2 assessment in breast cancer
por: Rakha, Emad A, et al.
Publicado: (2015)

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
por: Ellis, Paul, et al.
Publicado: (2009)

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
por: Cameron, David, et al.
Publicado: (2017)

Correction to: Trastuzumab administration during pregnancy: an update
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Summary version of the standards, options and recommendations for nonmetastatic breast cancer (updated January 2001)
por: Mauriac, L, et al.
Publicado: (2003)

Inter-institutional pathology consultations for breast cancer: impact on clinical oncology therapy recommendations
por: Price, J.A., et al.
Publicado: (2010)

Adherence to cancer prevention recommendations and risk of breast cancer in situ in the United Kingdom Biobank
por: Karavasiloglou, Nena, et al.
Publicado: (2022)

Cancer incidence in the United Kingdom: projections to the year 2030
por: Mistry, M, et al.
Publicado: (2011)

Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage
por: Verrill, Mark, et al.
Publicado: (2020)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

Trastuzumab Cures Cancer and Disrupts the Practice of Cardiology
por: Steingart, Richard M., et al.
Publicado: (2019)

Cancer mortality in the United Kingdom: projections to the year 2025
por: Olsen, A H, et al.
Publicado: (2008)

Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer
por: DOWN, SUE K., et al.
Publicado: (2014)

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
por: Swain, S M, et al.
Publicado: (2018)

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
por: Canney, P. A., et al.
Publicado: (1985)

Trastuzumab deruxtecan for breast cancer
Publicado: (2022)

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
por: Bouwer, N. I., et al.
Publicado: (2021)

Cancer prevalence in the United Kingdom: estimates for 2008
por: Maddams, J, et al.
Publicado: (2009)

Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines
por: Mehanna, H, et al.
Publicado: (2016)

Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer network Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?
por: Webster, R M, et al.
Publicado: (2012)

Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review
por: Egloff, Heidi, et al.
Publicado: (2018)

Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
por: Matsumoto, Toshihiko, et al.
Publicado: (2022)

Chemotherapy for early-stage breast cancer: a brief history
por: Verrill, M
Publicado: (2009)

Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.
por: Canney, P. A., et al.
Publicado: (1984)

Cannot write session to /tmp/vufind_sessions/sess_jnmv828our96uoqnegkd0gbj3p